Cetus Oncology Corp.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cetus Oncology Corp.
Amgen’s $125 Per Share Offer For Onyx Reflects Kyprolis Uncertainty
Amgen will acquire the cancer company Onyx for $125 per share, or $10.4 billion. That's higher than the $120 per share Amgen originally offered, but less than some investors and analysts thought obtainable.
Roche Pounces On Market-Weakened Illumina
Roche’s $5.7 billion hostile takeover offer for Illumina is opportunistic as well as strategic. It is a validation of Illumina’s long-term growth potential but also takes advantage of a depressed stock price due to the global economic slowdown and cutbacks in government funding that have hurt Illumina and other providers of gene sequencing instrumentation.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.